RU2005140285A - Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения - Google Patents
Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения Download PDFInfo
- Publication number
- RU2005140285A RU2005140285A RU2005140285/15A RU2005140285A RU2005140285A RU 2005140285 A RU2005140285 A RU 2005140285A RU 2005140285/15 A RU2005140285/15 A RU 2005140285/15A RU 2005140285 A RU2005140285 A RU 2005140285A RU 2005140285 A RU2005140285 A RU 2005140285A
- Authority
- RU
- Russia
- Prior art keywords
- mood
- treatment
- stabilizer
- composition
- oxcarbamazepine
- Prior art date
Links
- 229940127237 mood stabilizer Drugs 0.000 title claims 7
- 239000004050 mood stabilizer Substances 0.000 title claims 7
- 208000019022 Mood disease Diseases 0.000 title claims 6
- 239000000203 mixture Substances 0.000 claims 12
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 4
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 4
- 229960000623 carbamazepine Drugs 0.000 claims 4
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 4
- 229960003120 clonazepam Drugs 0.000 claims 4
- 229960002870 gabapentin Drugs 0.000 claims 4
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 4
- 229960001848 lamotrigine Drugs 0.000 claims 4
- 229960004002 levetiracetam Drugs 0.000 claims 4
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229960004394 topiramate Drugs 0.000 claims 4
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 4
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 4
- 229960002911 zonisamide Drugs 0.000 claims 4
- 229940126601 medicinal product Drugs 0.000 claims 3
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 claims 2
- CDONPRYEWWPREK-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-1h-quinolin-2-one Chemical group ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)C=CC4=CC=3)CC2)=C1Cl CDONPRYEWWPREK-UHFFFAOYSA-N 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- 229960004372 aripiprazole Drugs 0.000 claims 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- 229940028937 divalproex sodium Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960001078 lithium Drugs 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Композиция, содержащая, по меньшей мере, одно производное карбостирила в комбинации, по меньшей мере, с одним стабилизатором настроения.
2. Композиция по п.1, в которой производное карбостирила представляет собой стабилизатор допамин-серотониновой системы.
3. Композиция по п.2, в которой производное карбостирила представляет собой арипипразол или его метаболит.
4. Композиция по п.3, в которой метаболитом арипипразола является дегидроарипипразол, DM-1458, DM-1451, DM-1452, DM-1454 или DCPP.
5. Композиция по п.1, в которой, по меньшей мере, один стабилизатор настроения представляет собой литий, вальпроевую кислоту, дивальпроекс натрия, карбамазепин, окскарбамазепин, зонисамид, ламотригин, топирамат, габапентин, леветирацетам или клоназепам, или его соль.
6. Композиция по п.1, в которой, по меньшей мере, один стабилизатор настроения представляет собой карбамазепин, окскарбамазепин, зонисамид, ламотригин, топирамат, габапентин, леветирацетам или клоназепам, или его соль.
7. Композиция по п.1, которая дополнительно содержит, по меньшей мере, один фармацевтически приемлемый носитель.
8. Применение композиций по любому из пп.1-7 в приготовлении лекарственного средства, предназначенного для лечения расстройств настроения.
9. Применение композиций по любому из пп.1-7 в приготовлении лекарственного средства, предназначенного для лечения биполярного расстройства.
10. Применение композиций по любому из пп.1-7 в приготовлении лекарственного средства, предназначенного для лечения маниакального синдрома.
11. Способ лечения расстройства настроения у пациента, включающий введение любой из композиций по пп.1-7 в фармацевтически приемлемом носителе, где количество данной композиции является эффективным для лечения расстройства настроения у пациента.
12. Способ лечения расстройства настроения у пациента, включающий раздельное введение первого количества производного карбостирила и второго количества стабилизатора настроения, где введение является эффективным для лечения расстройства настроения у пациента.
13. Способ по п.12, в котором производное карбостирила представляет собой арипипразол или его метаболит.
14. Способ по п.13, в котором метаболит арипипразола представляет собой дегидроарипипразол, DM-1458, DM-1451, DM-1452, DM-1454 или DCPP.
15. Способ по п.12, при котором стабилизатор настроения представляет собой литий, вальпроевую кислоту, дивальпроекс натрия, карбамазепин, окскарбамазепин, зонисамид, ламотригин, топирамат, габапентин, леветирацетам или клоназепам, или его соль.
16. Способ по п.15, при котором стабилизатор настроения представляет собой карбамазепин, окскарбамазепин, зонисамид, ламотригин, топирамат, габапентин, леветирацетам или клоназепам, или его соль.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47337803P | 2003-05-23 | 2003-05-23 | |
US60/473,378 | 2003-05-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005140285A true RU2005140285A (ru) | 2006-06-10 |
RU2359675C2 RU2359675C2 (ru) | 2009-06-27 |
Family
ID=33490596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005140285A RU2359675C2 (ru) | 2003-05-23 | 2004-05-19 | Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения |
Country Status (27)
Country | Link |
---|---|
US (5) | US9125939B2 (ru) |
EP (2) | EP2601953A1 (ru) |
JP (2) | JP4693778B2 (ru) |
KR (1) | KR100881046B1 (ru) |
CN (5) | CN102172401A (ru) |
AU (1) | AU2004243096B2 (ru) |
BR (1) | BRPI0410786A (ru) |
CA (1) | CA2526562C (ru) |
CO (1) | CO5630025A2 (ru) |
CY (1) | CY1118313T1 (ru) |
DK (1) | DK1626721T3 (ru) |
EC (1) | ECSP056182A (ru) |
ES (1) | ES2609382T3 (ru) |
GE (1) | GEP20084567B (ru) |
HU (1) | HUE030014T2 (ru) |
IL (3) | IL171414A (ru) |
LT (1) | LT1626721T (ru) |
MX (1) | MXPA05012538A (ru) |
NO (1) | NO332764B1 (ru) |
NZ (1) | NZ542985A (ru) |
PL (1) | PL1626721T3 (ru) |
PT (1) | PT1626721T (ru) |
RU (1) | RU2359675C2 (ru) |
TW (1) | TWI342776B (ru) |
UA (1) | UA92453C2 (ru) |
WO (1) | WO2004105682A2 (ru) |
ZA (1) | ZA200508306B (ru) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053092B2 (en) * | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
NZ556779A (en) | 2002-12-27 | 2008-12-24 | Otsuka Pharma Co Ltd | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
DE05815688T1 (de) | 2005-01-27 | 2008-06-26 | Alembic Ltd. | Levetiracetam-formulierung mit verlängerter freisetzung |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
DK1909764T3 (da) * | 2005-07-26 | 2014-12-15 | Ucb Pharma Sa | Farmaceutisk sammensætninger omfattende levetiracetam og fremgangsmåde til deres fremstilling |
US20080014264A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
US8247420B2 (en) * | 2007-05-21 | 2012-08-21 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
CN102413830A (zh) | 2009-02-26 | 2012-04-11 | 雷维瓦药品公司 | 利用芳基哌嗪衍生物的组合物、合成及方法 |
WO2010151711A1 (en) * | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
PL2445502T5 (pl) * | 2009-06-25 | 2023-03-13 | Alkermes Pharma Ireland Limited | Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych |
ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
CA2826765C (en) * | 2011-02-09 | 2021-04-06 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
US9034867B2 (en) | 2011-03-18 | 2015-05-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
CA2858787C (en) | 2011-12-15 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of tertiary amine compounds |
JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
CA2867137C (en) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN103550778B (zh) * | 2013-11-18 | 2015-12-30 | 四川科瑞德制药有限公司 | 一种治疗情感性精神障碍疾病的药物组合物 |
AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
CN108623520A (zh) * | 2017-03-16 | 2018-10-09 | 重庆医药工业研究院有限责任公司 | 阿立哌唑缩醛月桂酸酯的制备方法 |
JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
JP7211136B2 (ja) * | 2019-02-14 | 2023-01-24 | ニプロ株式会社 | 錠剤、および、その製造方法 |
US20240009181A1 (en) * | 2022-07-08 | 2024-01-11 | Jason Eric Schiffman | Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2608788B2 (ja) | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
JPH04284524A (ja) * | 1991-03-14 | 1992-10-09 | Matsushita Electric Ind Co Ltd | キー入力装置 |
WO1997035584A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
CZ20004280A3 (cs) * | 1998-05-29 | 2001-09-12 | Eli Lilly And Company | Lék pro léčbu bipolárních poruch a farmaceutický prostředek |
US20030027817A1 (en) | 1998-05-29 | 2003-02-06 | Tollefson Gary Dennis | Combination therapy for treatment of bipolar disorders |
DK1158973T3 (da) | 1999-02-24 | 2005-05-30 | Univ Cincinnati | Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser |
JP2002541098A (ja) | 1999-04-06 | 2002-12-03 | セプラコア インコーポレーテッド | ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物 |
AU2002232470B2 (en) * | 2001-01-02 | 2005-11-03 | Pharmacia & Upjohn Company Llc | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
EP1404342A1 (en) | 2001-04-26 | 2004-04-07 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
WO2003066039A1 (en) | 2002-02-08 | 2003-08-14 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
NZ556779A (en) * | 2002-12-27 | 2008-12-24 | Otsuka Pharma Co Ltd | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
MXPA05012317A (es) | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas. |
-
2004
- 2004-05-19 CN CN2011100658667A patent/CN102172401A/zh active Pending
- 2004-05-19 NZ NZ542985A patent/NZ542985A/en unknown
- 2004-05-19 JP JP2006532509A patent/JP4693778B2/ja not_active Expired - Lifetime
- 2004-05-19 DK DK04785621.6T patent/DK1626721T3/en active
- 2004-05-19 CA CA 2526562 patent/CA2526562C/en not_active Expired - Lifetime
- 2004-05-19 UA UAA200512389A patent/UA92453C2/ru unknown
- 2004-05-19 WO PCT/US2004/013308 patent/WO2004105682A2/en active Application Filing
- 2004-05-19 US US10/556,600 patent/US9125939B2/en active Active
- 2004-05-19 AU AU2004243096A patent/AU2004243096B2/en not_active Ceased
- 2004-05-19 CN CNA2004800141038A patent/CN1794994A/zh active Pending
- 2004-05-19 PL PL04785621T patent/PL1626721T3/pl unknown
- 2004-05-19 RU RU2005140285A patent/RU2359675C2/ru not_active IP Right Cessation
- 2004-05-19 CN CN2010105130520A patent/CN102000336A/zh active Pending
- 2004-05-19 CN CN2011100658597A patent/CN102166359A/zh active Pending
- 2004-05-19 ES ES04785621.6T patent/ES2609382T3/es not_active Expired - Lifetime
- 2004-05-19 EP EP20130157570 patent/EP2601953A1/en not_active Withdrawn
- 2004-05-19 LT LTEP04785621.6T patent/LT1626721T/lt unknown
- 2004-05-19 EP EP04785621.6A patent/EP1626721B1/en not_active Revoked
- 2004-05-19 PT PT47856216T patent/PT1626721T/pt unknown
- 2004-05-19 BR BRPI0410786 patent/BRPI0410786A/pt active Search and Examination
- 2004-05-19 MX MXPA05012538A patent/MXPA05012538A/es active IP Right Grant
- 2004-05-19 GE GEAP2004009073 patent/GEP20084567B/en unknown
- 2004-05-19 ZA ZA200508306A patent/ZA200508306B/en unknown
- 2004-05-19 HU HUE04785621A patent/HUE030014T2/en unknown
- 2004-05-19 CN CN2011100660455A patent/CN102172402A/zh active Pending
- 2004-05-19 KR KR20057022168A patent/KR100881046B1/ko active IP Right Grant
- 2004-05-21 TW TW93114483A patent/TWI342776B/zh not_active IP Right Cessation
-
2005
- 2005-10-16 IL IL171414A patent/IL171414A/en not_active IP Right Cessation
- 2005-11-03 NO NO20055152A patent/NO332764B1/no not_active IP Right Cessation
- 2005-11-21 CO CO05117551A patent/CO5630025A2/es unknown
- 2005-11-21 EC ECSP056182 patent/ECSP056182A/es unknown
-
2010
- 2010-12-28 JP JP2010292277A patent/JP2011093920A/ja active Pending
-
2011
- 2011-03-03 IL IL211529A patent/IL211529A0/en unknown
-
2013
- 2013-12-19 IL IL230025A patent/IL230025A0/en unknown
-
2015
- 2015-07-10 US US14/795,963 patent/US20160030423A1/en not_active Abandoned
-
2016
- 2016-12-09 CY CY20161101271T patent/CY1118313T1/el unknown
-
2019
- 2019-09-20 US US16/576,806 patent/US20200246332A1/en not_active Abandoned
-
2020
- 2020-11-04 US US16/949,571 patent/US20210308126A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/176,533 patent/US20240024310A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005140285A (ru) | Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения | |
JP6353577B2 (ja) | 組み合わせ組成物 | |
EA200800056A1 (ru) | Каннабиноидный активный фармацевтический ингредиент для лекарственных форм | |
JP2012102118A (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも1つのアミノ酸を含む組成物および使用法 | |
BR0109336A (pt) | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico | |
CN106659711A (zh) | 呈现长期稳定性的褪黑素注射剂的持久制剂 | |
JP2014515408A5 (ru) | ||
EA200501105A1 (ru) | Фармацевтическая композиция | |
KR102335919B1 (ko) | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 | |
Manitpisitkul et al. | Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment | |
KR20120061841A (ko) | 동통 억제용 의약 조성물 | |
BR9913746E8 (pt) | derivado de piridínio, processo para a preparação do composto, uso do composto, composição farmacêutica para o tratamento de complicações diabéticas e doenças relacionadas ao envelhecimento, processo para preparação de uma formulação parenteral,processo para o tratamento de um paciente diabético pela ruptura de um age pré-formado dentro do paciente,e,processo de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento. | |
KR20070003995A (ko) | 감소된 간독성을 갖는 조성물 | |
RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
MXPA04007183A (es) | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. | |
Lapointe | Iron supplementation in the intensive care unit: when, how much, and by what route? | |
AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
MA28036A1 (fr) | Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil | |
BRPI0410374A (pt) | composição farmacêutica que compreende valsartano | |
JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
JP5376785B2 (ja) | 医薬組成物 | |
JP4627580B2 (ja) | 肝疾患処置剤 | |
AR046464A1 (es) | Multiparticulas de liberacion controlada con mejoradores de la disolucion | |
US20080293804A1 (en) | Pharmaceutical Nasal Spray Formulation of Acetaminophen (paracetamol) | |
JP4587637B2 (ja) | 神経ペプチドの産生・放出抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190520 |